Arix Bioscience PLC has announced that Andrew Smith, a Non-Executive Director of the company, has purchased 25,000 ordinary shares of 0.001 pence each in the company at a price of £1.13 per share. The transaction took place on November 9, 2023, on the London Stock Exchange. The aggregated volume of the transaction was 25,000 shares, with a total price of £28,174.25. The reason for the notification is that it is a requirement to disclose transactions by persons discharging managerial responsibilities and persons closely associated with them. Arix Bioscience is a biotechnology company.